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average length of stay (ALOS) (15.2 days vs. 18.3 days) increased
following colectomy, while mean number of admissions did not
increase signiﬁcantly. The same trend was seen in UC-related
costs ($6,957 vs. $12,422) and lengths of stay (7.6 days vs. 11.7
days). CONCLUSION: Inpatient hospital utilization and subse-
quent costs increased during the 12-month period following
colectomy in the Medicare population. Additional analyses are
needed to determine the extent of these services and reasons for
increased inpatient utilization.
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OBJECTIVES: The nursing for patient with acute pancreatitis
lies in many hospitals on nursing tradition using task centered
approach which is not meeting the evidence-based requirements
of today nursing. The medical professional development in treat-
ing pancreatitis demands the use of evidence based guidelines in
nursing. Our study examines the importance of using and evalu-
ating the evidence based guidelines for patient during the naso-
jejunal tube feeding. METHODS: In a retrospective data analysis
the effectiveness of nursing process during naso-jejunal tube
feeding was evaluated by a self-developed special index for
nursing process. The examined period was between January
1–February 31, 2003 in a district hospital in Budapest
(Hungary). Some outcomes measures, like changing in the nutri-
tional status of the patients, energy level, adequacy level of
nurturing process. The data analysis was done by SPSS 11.0.
RESULTS: During the period 144 patient were nurtured with
naso-jejunal tube because of acute pancreatitis. 103 cases were
appropriate for further analysis. The average age was 54 years
(Rmax: 22, Rmin: 90), male: 52, female 51. The patients were
grouped into three groups (normal, under and over nurtured)
based on BMI, Harris Benedict index, Broca index. The main
signiﬁcant aspects in the patient outcomes were: ﬂuent informa-
tion ﬂow among nurses caring for the given patient, the balanced
and continuous nutritional nursing process, planed nutrition.
There was a clear signiﬁcant association between adverse patient
outcome and poor nursing process (p = 0.0034). CONCLU-
SION: The best evidence based guideline may only improve the
effectiveness of nursing process if the whole process is continu-
ously controlled. The results also emphasize the nutrition based
on individual needs, guideline based nursing process, the tool for
continuous evaluation of the nurturing process.
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OBJECTIVES: To research the usage of over-the-counter (OTC)
nonselective non-steroidal antiinﬂamaroty drugs (nsNSAID)
relating to the Guidelines and the rational use of drugs in patients
with gastrointestinal (GI) diseases, morbidity and hospitalisa-
tions. METHODS: This is a retrospective study for the period
2004–2006. The source of data was the database of Public Phar-
macy Pozarevac and Public Health Centar Pozarevac, Pozarevac
(Branicevo region; 200503 inhabitans). Type of data: the number
of GI hospitalisations and the number of patients with GI dis-
eases; DDD methodology (DDD/1000 inhabitants/day) for OTC
nsNSAID. RESULTS: The number of GI disease patients was
decreased: 9636 (2004), 7982 (2005), 7806 (2006). The decrease
was 17.16% (2005) and 18.99% (2006) compared to 2004. The
number of patients who used diclofenac or other nsNSAID with
proton pump inhibitors or H2-receptor antagonists (according to
Guidelines) was increased during opserved period: 817, 931,
1187, respectively; with a great increase of 45.29% (2006 com-
pered to 2004). But, the number of GI hospitalisations was
increased with 10.18% (2005) and 15.06% (2006) related to
2004. The costs of GI hospitalisations were grown: 29.52%
(2005) and 121.32% (2006), compared to the costs in 2004.
Considering the utilisation of OTC diclofenac (the most frequent
used nsNSAID) in DDD unit, we may see an increase: 62,279;
65,983; 82,911, respectively 2004–2006. We assume that this
pharmacoepidemiology data is directly related to the increases of
hospitalisation load. CONCLUSION: There is an improvement
of rational drug usage related to Guidelines, but the increase of
GI hospitalisation and diclofenac self-medication pointed out
that this relation must be more persistent in Branicevo region. It
will be usefull to educate the patients and the pharmacists, about
the adverse drug reaction (ADR) of the nsNSAID. This way
would be the right modality to improve the rational drug usage
of nsNSAID aiming to improve the quality of life and decrease
costs.
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OBJECTIVES: To assess the impact of maintenance versus epi-
sodic inﬂiximab therapy on hospitalizations and surgery in
patients with Crohn’s disease (CD). METHODS: A retrospective
analysis of claims data was conducted from the Marketscan
Commercial Claims and Encounters database from 2000 to 2003
for claimants with CD (ICD-9 codes, 555.0, 555.1, 555.2 or
555.9) who had an induction regimen (3 infusions) of inﬂiximab
in 2003. Continuous enrollment for 12 months pre- and 12
months post- the index infusion date in 2003 was required.
Patients were excluded if they had inﬂiximab infusions in 2001
or 2002. Cohort analyses were conducted for three distinct
cohorts: 1) 1–2 inﬂiximab infusions; 2) 3–4 inﬂiximab infusions;
3) 5 or more inﬂiximab infusions. RESULTS: Analyses were
conducted on 126 patients who met the inclusion criteria. The
majority of patients were female (53.2%) and the mean age was
49.5 years. Among the cohort with 5 or more inﬂiximab infu-
sions (n = 34), 20.6% required hospitalization, as compared to
37.5% of the cohort with 1–2 infusions (n = 48) and 34.1% of
the cohort with 3–4 infusions (n = 44). The cohort with 5 or
more inﬂiximab infusions also had fewer mean hospitalizations
(1.29 vs. 1.83 and 1.47, ns), and shorter lengths of stay (5.11
days vs. 5.64 days and 5.91 days; ns). In addition, the percentage
of patients requiring surgery was decreased for the 5 or more
infusion cohort (24%) as compared with the other cohorts (40%
each). CONCLUSION: Although not-signiﬁcant, the results of
this analysis indicate that when treating CD with a maintenance
schedule of inﬂiximab, the number and length of hospitalizations
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